Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Druggability of Proteins in Oncology Targeting Immune Cell Signaling
share announcement

Druggability of Proteins in Oncology Targeting Immune Cell Signaling

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 2189

Special Issue Editor

Dr. Victoria Klepsch

E-Mail Website
Guest Editor
Institute of Cell Genetics, Department for Genetics and Pharmacology, Peter Mayr Straße 1a, A-6020 Innsbruck, Austria
Interests: tumor immunology; immunotherapy; molecular mechanisms of T lymphocyte signaling; innovative immunological therapeutic concepts; CRISPR/Cas9-mediated gene editing

Special Issue Information

Dear Colleagues,

This Special Issue on “Druggability of Proteins in Oncology Targeting Immune Cell Signaling” will mainly focus on known and novel druggable proteins and their potential to induce a potent antitumor immunity for cancer immunotherapy.

Proteins important for an effective antitumor immune response have been extensively studied in the past two decades and have been shown to induce great response rates in some cancer patients. Still, new pathways/proteins, combinatorial approaches, and methods to target druggable proteins are envisioned as a way forward to extend the benefits of clinical immuno-oncology therapies to a larger number of cancer patients.

We cordially invite authors in the field to submit original research or review articles pertaining to this important and fast-progressing field of biomedicine.

Dr. Victoria Klepsch
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • tumor immunology
  • druggability of proteins
  • immune cell signaling
  • antitumor immunity
  • immunotherapy
  • combinatorial therapy

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

18 pages, 2342 KiB  
Article
Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96
by Christina Boch, Markus Reschke, Frederik Igney, Peter Maier, Philipp Müller, Sarah Danklmaier, Krishna Das, Tamara Hofer, Guido Wollmann and Wolfgang Rist
Biomedicines 2022, 10(9), 2146; https://doi.org/10.3390/biomedicines10092146 - 1 Sep 2022
Viewed by 1952
Abstract
One important prerequisite for developing a therapeutic monoclonal antibody is to evaluate its in vivo efficacy. We tested the therapeutic potential of an anti-CD96 antibody alone or in combination with an anti-PD-1 antibody in a mouse colon cancer model. Early anti-PD-1 treatment significantly [...] Read more.
One important prerequisite for developing a therapeutic monoclonal antibody is to evaluate its in vivo efficacy. We tested the therapeutic potential of an anti-CD96 antibody alone or in combination with an anti-PD-1 antibody in a mouse colon cancer model. Early anti-PD-1 treatment significantly decreased tumor growth and the combination with anti-CD96 further increased the therapeutic benefit, while anti-CD96 treatment alone had no effect. In late therapeutic settings, the treatment combination resulted in enhanced CD8+ T cell infiltration of tumors and an increased CD8/Treg ratio. Measured anti-PD-1 concentrations were as expected in animals treated with anti-PD-1 alone, but lower at later time points in animals receiving combination treatment. Moreover, anti-CD96 concentrations dropped dramatically after 10 days and were undetectable thereafter in most animals due to the occurrence of anti-drug antibodies that were increasing antibody clearance. Comparison of the anti-PD-1 concentrations with tumor growth showed that higher antibody concentrations in plasma correlated with better therapeutic efficacy. The therapeutic effect of anti-CD96 treatment could not be evaluated, because plasma concentrations were too low. Our findings strongly support the notion of measuring both plasma concentration and anti-drug antibody formation throughout in vivo studies, in order to interpret pharmacodynamic data correctly. Full article
(This article belongs to the Special Issue Druggability of Proteins in Oncology Targeting Immune Cell Signaling)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop